Eris Lifesciences Limited (ERIS.BO)
INR 1321.05
(3.6%)
INR 1321.05
(3.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.94 Billion INR | -37.62% |
| 2022 | 8.82 Billion INR | 37.81% |
| 2021 | 6.4 Billion INR | 13.93% |
| 2020 | 5.62 Billion INR | 1.09% |
| 2019 | 5.55 Billion INR | 10.95% |
| 2018 | 5.01 Billion INR | 27.06% |
| 2017 | 3.94 Billion INR | -0.35% |
| 2016 | 3.95 Billion INR | 15.64% |
| 2015 | 3.42 Billion INR | -0.33% |
| 2014 | 3.43 Billion INR | 9.3% |
| 2013 | 3.14 Billion INR | 35.77% |
| 2012 | 2.31 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.68 Billion INR | 5.26% |
| 2024 Q1 | 1.56 Billion INR | -13.92% |
| 2023 Q2 | 2.66 Billion INR | 5.57% |
| 2023 Q4 | 1.81 Billion INR | -31.34% |
| 2023 FY | 5.5 Billion INR | -37.62% |
| 2023 Q1 | 2.52 Billion INR | 8.66% |
| 2023 Q3 | 2.64 Billion INR | -0.77% |
| 2022 Q4 | 2.32 Billion INR | 4.91% |
| 2022 FY | 8.82 Billion INR | 37.81% |
| 2022 Q3 | 2.21 Billion INR | -2.22% |
| 2022 Q2 | 2.26 Billion INR | 12.72% |
| 2022 Q1 | 2.01 Billion INR | 30.94% |
| 2021 Q1 | 1.62 Billion INR | 29.21% |
| 2021 Q3 | 1.61 Billion INR | -0.17% |
| 2021 FY | 6.4 Billion INR | 13.93% |
| 2021 Q2 | 1.62 Billion INR | -0.43% |
| 2021 Q4 | 1.53 Billion INR | -5.03% |
| 2020 Q4 | 1.25 Billion INR | -17.11% |
| 2020 Q1 | 1.36 Billion INR | 4.03% |
| 2020 Q2 | 1.47 Billion INR | 7.63% |
| 2020 Q3 | 1.51 Billion INR | 3.23% |
| 2020 FY | 5.62 Billion INR | 1.09% |
| 2019 Q3 | 1.54 Billion INR | 13.34% |
| 2019 FY | 5.55 Billion INR | 10.95% |
| 2019 Q4 | 1.31 Billion INR | -15.09% |
| 2019 Q2 | 1.36 Billion INR | 2.73% |
| 2019 Q1 | 1.32 Billion INR | 9.53% |
| 2018 Q3 | 1.25 Billion INR | -1.91% |
| 2018 FY | 5.01 Billion INR | 27.06% |
| 2018 Q4 | 1.21 Billion INR | -2.98% |
| 2018 Q2 | 1.27 Billion INR | 0.52% |
| 2018 Q1 | 1.26 Billion INR | 11.06% |
| 2017 Q4 | 1.14 Billion INR | 14.93% |
| 2017 FY | 3.94 Billion INR | -0.35% |
| 2017 Q1 | 909.36 Million INR | 4.64% |
| 2017 Q2 | 981.95 Million INR | 7.98% |
| 2017 Q3 | 994.48 Million INR | 1.28% |
| 2016 Q3 | 959.74 Million INR | -9.8% |
| 2016 FY | 3.95 Billion INR | 15.64% |
| 2016 Q4 | 869.05 Million INR | -9.45% |
| 2016 Q2 | 1.06 Billion INR | 27.71% |
| 2016 Q1 | 833.15 Million INR | 0.0% |
| 2015 FY | 3.42 Billion INR | -0.33% |
| 2014 FY | 3.43 Billion INR | 9.3% |
| 2013 FY | 3.14 Billion INR | 35.77% |
| 2012 FY | 2.31 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 68.853% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 87.402% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 57.537% |
| Granules India Limited | 7.18 Billion INR | 31.18% |
| Indoco Remedies Limited | 4.74 Billion INR | -4.089% |
| Achyut Healthcare Limited | 1.6 Million INR | -307105.718% |
| Ajanta Pharma Limited | 30.46 Billion INR | 83.774% |
| Alkem Laboratories Limited | 32.83 Billion INR | 84.946% |
| Alpa Laboratories Limited | 156.14 Million INR | -3065.568% |
| Brooks Laboratories Limited | 51.18 Million INR | -9557.952% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -90.084% |
| Bajaj HealthCare Limited | 985.34 Million INR | -401.646% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -248.285% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 94.845% |
| FDC Limited | 5.34 Billion INR | 7.583% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 92.684% |
| Gufic Biosciences Limited | 1.07 Billion INR | -358.652% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -132.698% |
| Ipca Laboratories Limited | 13.91 Billion INR | 64.477% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -539.11% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -10609.204% |
| Lasa Supergenerics Limited | 291.17 Million INR | -1597.59% |
| Laurus Labs Limited | 3.01 Billion INR | -64.174% |
| Lupin Limited | 95.67 Billion INR | 94.834% |
| Mankind Pharma Limited | 23.15 Billion INR | 78.651% |
| Medicamen Biotech Limited | 335.16 Million INR | -1374.769% |
| Medico Remedies Limited | 161.84 Million INR | -2954.139% |
| Megasoft Limited | 49.52 Million INR | -9880.092% |
| NATCO Pharma Limited | 10.05 Billion INR | 50.856% |
| Piramal Pharma Limited | 19.91 Billion INR | 75.179% |
| RPG Life Sciences Limited | 1.63 Billion INR | -202.228% |
| Sigachi Industries Limited | 579.88 Million INR | -752.397% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 96.794% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -252.365% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -424.506% |
| Unichem Laboratories Limited | 6.72 Billion INR | 26.509% |
| Wanbury Limited | 1.16 Billion INR | -325.775% |
| Windlas Biotech Limited | 1 Billion INR | -391.097% |
| ZIM Laboratories Limited | 1.01 Billion INR | -387.923% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 88.551% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -60.652% |
| Divi's Laboratories Limited | 14.17 Billion INR | 65.117% |
| Hester Biosciences Limited | 908.84 Million INR | -443.874% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -65.018% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -349.772% |
| Bal Pharma Limited | 389.89 Million INR | -1167.778% |
| Strides Pharma Science Limited | 9.16 Billion INR | 46.051% |
| Venus Remedies Limited | 1.91 Billion INR | -157.944% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -60.777% |
| Nectar Lifesciences Limited | 625.55 Million INR | -690.175% |
| Shilpa Medicare Limited | 2.18 Billion INR | -126.679% |
| Aarti Drugs Limited | 1.16 Billion INR | -323.386% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -349.849% |
| Suven Life Sciences Limited | 109.75 Million INR | -4403.818% |
| Ind-Swift Limited | 946.56 Million INR | -422.197% |
| Valiant Laboratories Limited | 36.28 Million INR | -13521.042% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 41.275% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -7.932% |
| Themis Medicare Limited | 782.85 Million INR | -531.399% |
| Hikal Limited | 2.48 Billion INR | -98.804% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 76.926% |
| Sequent Scientific Limited | 2.9 Billion INR | -70.34% |
| Novartis India Limited | 470.1 Million INR | -951.466% |
| Wockhardt Limited | 6.4 Billion INR | 22.767% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 65.802% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -30393.719% |
| Neuland Laboratories Limited | 2.92 Billion INR | -68.716% |
| Morepen Laboratories Limited | 1.98 Billion INR | -148.708% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -1098.501% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -631.045% |